Charles Schwab’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $227M | Buy |
755,377
+82,021
| +12% | +$24.7M | 0.03% | 419 |
|
|
2026
Q1 | $223M | Buy |
673,356
+25,517
| +4% | +$8.68M | 0.03% | 387 |
|
|
2025
Q4 | $258M | Buy |
647,839
+29,069
| +5% | +$12.9M | 0.04% | 348 |
|
|
2025
Q3 | $282M | Buy |
618,770
+47,023
| +8% | +$19.1M | 0.05% | 330 |
|
|
2025
Q2 | $186M | Buy |
571,747
+25,105
| +5% | +$6.95M | 0.03% | 417 |
|
|
2025
Q1 | $148M | Buy |
546,642
+32,680
| +6% | +$8.4M | 0.03% | 478 |
|
|
2024
Q4 | $121M | Buy |
513,962
+26,614
| +5% | +$7M | 0.02% | 563 |
|
|
2024
Q3 | $134M | Buy |
487,348
+16,756
| +4% | +$4.36M | 0.03% | 518 |
|
|
2024
Q2 | $114M | Buy |
470,592
+23,032
| +5% | +$3.64M | 0.02% | 578 |
|
|
2024
Q1 | $66.9M | Buy |
447,560
+9,256
| +2% | +$1.54M | 0.02% | 825 |
|
|
2023
Q4 | $83.9M | Buy |
438,304
+19,324
| +5% | +$3.29M | 0.02% | 646 |
|
|
2023
Q3 | $74.2M | Buy |
418,980
+2,836
| +0.7% | +$541K | 0.02% | 644 |
|
|
2023
Q2 | $79M | Buy |
416,144
+10,781
| +3% | +$2.14M | 0.02% | 610 |
|
|
2023
Q1 | $81.2M | Buy |
405,363
+4,787
| +1% | +$1.01M | 0.02% | 581 |
|
|
2022
Q4 | $95.2M | Buy |
400,576
+21,711
| +6% | +$4.63M | 0.03% | 497 |
|
|
2022
Q3 | $75.8M | Buy |
378,865
+2,568
| +0.7% | +$490K | 0.03% | 545 |
|
|
2022
Q2 | $54.9M | Buy |
376,297
+3,674
| +1% | +$521K | 0.02% | 695 |
|
|
2022
Q1 | $60.8M | Buy |
372,623
+9,662
| +3% | +$1.47M | 0.02% | 751 |
|
|
2021
Q4 | $61.6M | Buy |
362,961
+10,146
| +3% | +$1.89M | 0.02% | 762 |
|
|
2021
Q3 | $66.6M | Buy |
352,815
+9,484
| +3% | +$1.78M | 0.02% | 694 |
|
|
2021
Q2 | $58.2M | Buy |
343,331
+9,118
| +3% | +$1.34M | 0.02% | 759 |
|
|
2021
Q1 | $47.2M | Sell |
334,213
-66,063
| -17% | -$9.94M | 0.02% | 873 |
|
|
2020
Q4 | $52M | Sell |
400,276
-303
| -0.1% | -$40.5K | 0.02% | 751 |
|
|
2020
Q3 | $58.3M | Sell |
400,579
-229,065
| -36% | -$32.6M | 0.03% | 581 |
|
|
2020
Q2 | $93.3M | Buy |
629,644
+18,825
| +3% | +$2.54M | 0.05% | 374 |
|
|
2020
Q1 | $66.5M | Buy |
610,819
+10,041
| +2% | +$1.16M | 0.04% | 418 |
|
|
2019
Q4 | $69.2M | Buy |
600,778
+9,278
| +2% | +$925K | 0.04% | 463 |
|
|
2019
Q3 | $47.6M | Buy |
591,500
+99,325
| +20% | +$7.86M | 0.03% | 617 |
|
|
2019
Q2 | $35.7M | Buy |
492,175
+21,151
| +4% | +$1.62M | 0.02% | 759 |
|
|
2019
Q1 | $44M | Buy |
471,024
+114,879
| +32% | +$9.61M | 0.03% | 608 |
|
|
2018
Q4 | $26M | Buy |
356,145
+13,099
| +4% | +$1.01M | 0.02% | 820 |
|
|
2018
Q3 | $30M | Buy |
343,046
+38,813
| +13% | +$3.9M | 0.02% | 868 |
|
|
2018
Q2 | $30M | Buy |
304,233
+26,881
| +10% | +$2.67M | 0.02% | 788 |
|
|
2018
Q1 | $33M | Buy |
277,352
+14,936
| +6% | +$1.93M | 0.03% | 689 |
|
|
2017
Q4 | $33.3M | Buy |
262,416
+17,866
| +7% | +$2.24M | 0.03% | 639 |
|
|
2017
Q3 | $28.7M | Buy |
244,550
+1,135
| +0.5% | +$96.9K | 0.03% | 666 |
|
|
2017
Q2 | $19.4M | Buy |
243,415
+60,906
| +33% | +$3.89M | 0.02% | 876 |
|
|
2017
Q1 | $9.35M | Sell |
182,509
-10,033
| -5% | -$464K | 0.01% | 1357 |
|
|
2016
Q4 | $7.21M | Buy |
192,542
+26,549
| +16% | +$1.11M | 0.01% | 1502 |
|
|
2016
Q3 | $11.3M | Buy |
165,993
+70,739
| +74% | +$4.99M | 0.01% | 1077 |
|
|
2016
Q2 | $5.29M | Sell |
95,254
-2,786
| -3% | -$176K | 0.01% | 1521 |
|
|
2016
Q1 | $6.15M | Buy |
98,040
+2,353
| +2% | +$156K | 0.01% | 1384 |
|
|
2015
Q4 | $9.01M | Buy |
95,687
+7,139
| +8% | +$662K | 0.01% | 1092 |
|
|
2015
Q3 | $7.12M | Sell |
88,548
-43,172
| -33% | -$4.8M | 0.01% | 1215 |
|
|
2015
Q2 | $15.8M | Buy |
131,720
+8,789
| +7% | +$1.05M | 0.02% | 692 |
|
|
2015
Q1 | $12.8M | Buy |
122,931
+17,548
| +17% | +$1.78M | 0.02% | 826 |
|
|
2014
Q4 | $10.2M | Buy |
105,383
+11,398
| +12% | +$1.06M | 0.02% | 875 |
|
|
2014
Q3 | $7.34M | Buy |
93,985
+5,237
| +6% | +$338K | 0.01% | 1044 |
|
|
2014
Q2 | $5.61M | Sell |
88,748
-78,241
| -47% | -$4.65M | 0.01% | 1300 |
|
|
2014
Q1 | $11.2M | Buy |
166,989
+24,454
| +17% | +$1.89M | 0.02% | 715 |
|
|
2013
Q4 | $9.17M | Buy |
142,535
+7,178
| +5% | +$428K | 0.02% | 782 |
|
|
2013
Q3 | $8.91M | Buy |
135,357
+6,214
| +5% | +$310K | 0.02% | 718 |
|
|
2013
Q2 | $4.26M | Buy |
+129,143
| New | +$3.44M | 0.01% | 1201 |
|
Other funds holding ALNY
Charles Schwab's ALNY Position: Q2 2026 in Review
Charles Schwab increased its Alnylam Pharmaceuticals (ALNY) stake by 12% in Q2 2026, buying an estimated $24.7M and bringing the position to 755,377 shares worth $227M. The position accounts for 0.03% of the portfolio, ranked #419.
Charles Schwab first reported a position in ALNY in Q2 2013 and has held it in 53 quarters since. The position peaked at $282M in Q3 2025. 785 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.
- Charles Schwab held 755,377 shares of Alnylam Pharmaceuticals worth $227M as of Q2 2026.
- Charles Schwab bought 82,021 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $24.7M.
- Alnylam Pharmaceuticals made up 0.03% of Charles Schwab's portfolio in Q2 2026, its #419 holding.
- Charles Schwab first reported a position in Alnylam Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
- Charles Schwab's Alnylam Pharmaceuticals position peaked at $282M in Q3 2025.
- 785 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.
Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.